Treatment-resistant depression has a specific definition in the clinical literature: the persistence of significant depressive symptoms after two or more adequate antidepressant trials. The word "adequate" is the one most people miss. It means a sufficient dose for a sufficient duration, usually six to eight weeks at the target dose, with reasonable adherence to the medication. Many people who think they have treatment-resistant depression actually haven't had an adequate trial yet.
The distinction matters because the next moves depend on it. If the trials weren't adequate, the answer is usually to finish a proper trial: adjust the dose to a clinically effective range, give it enough time, and reassess. If the trials were adequate and the response was still incomplete, the answer is different. That's when augmentation, switching classes, neurostimulation (TMS or ECT), and rapid-acting treatments (ketamine, esketamine) come into the conversation.
About one in three people with major depressive disorder won't reach remission on their first antidepressant. About one in three of those won't reach remission on the second. The pattern is well-known, the next-line options are well-studied, and most people who keep working through the sequence do eventually respond. Treatment-resistant depression is one of the conditions where persistence, through the right kinds of care, usually pays off.
This is the practical layer for treatment-resistant depression. What it actually means clinically. Why "treatment-resistant" often turns out to be something else once the picture is reviewed carefully. What the next-line options look like in practice. And how to find the kind of care that's set up to manage the sequence well.
What counts as a treatment trial
An "adequate trial" of an antidepressant requires three things. First, the dose has to reach what clinicians consider a clinically effective range for that specific medication. SSRIs and SNRIs vary in their effective dose ranges; the minimum dose listed on the package isn't always the dose that produces a response. Second, the trial has to last long enough. Six to eight weeks at target dose is the standard window for evaluating response. Earlier than that, the medication hasn't had enough time to demonstrate whether it's working. Third, adherence matters. Missing doses regularly, stopping early because of mild side effects, or taking the medication inconsistently means the trial is incomplete regardless of the calendar time elapsed.
By the formal definition, treatment-resistant depression requires two such adequate trials with insufficient response. Most clinicians and most major studies use this definition, though the specifics vary. Some require trials of two different antidepressant classes, some require trials of two medications within or across classes. The key is that the trials were adequate.
Why most "treatment-resistant" cases aren't
A meaningful share of cases that look treatment-resistant turn out to be something else when the history is reviewed in detail. The most common patterns:
Incomplete trials. The medication was taken for three weeks instead of eight. Or the dose was raised once and then held at a level below the effective range. Or side effects led to inconsistent dosing. In these cases, the right next step is usually to complete an adequate trial rather than jump to next-line treatments.
Missed bipolar disorder. Bipolar depression looks identical to unipolar depression from the outside, but it usually doesn't respond to SSRIs alone, and SSRIs alone can occasionally trigger mania in an undiagnosed case. People who have had past periods of unusually elevated mood, decreased need for sleep, racing thoughts, or impulsive behavior (even when those periods felt good and didn't seem like episodes) should have the bipolar question raised explicitly. The treatment path is different and far more effective when the diagnosis is right.
Untreated medical contributors. Thyroid dysfunction, sleep apnea, vitamin D deficiency, low-grade anemia, chronic pain, and certain chronic medical conditions can produce or worsen depressive symptoms in ways that don't respond to antidepressants alone. A medical workup is part of the treatment-resistant depression evaluation for this reason.
Active substance use. Ongoing alcohol use, cannabis use, or other substance use can blunt or reverse antidepressant response. Treating one without addressing the other usually doesn't work.
Active stressor. Antidepressants don't fix unrelenting external stressors. Active financial distress, a chronically difficult relationship, or an ongoing professional crisis can sustain depressive symptoms in ways that no medication will resolve on its own.
Working through these possibilities is part of what a thoughtful evaluation of "treatment-resistant" depression actually looks like. Often the answer is that the case isn't treatment-resistant in the strict sense. It's incompletely treated, missing a diagnosis, or carrying an unaddressed contributor.
The next-line options when treatment-resistance is real
When the trials really have been adequate, the diagnosis is right, and there's no untreated contributor, several next-line options have evidence.
Augmentation. Adding a second medication on top of the antidepressant. Lithium augmentation has long-standing evidence. Atypical antipsychotic augmentation (aripiprazole, brexpiprazole, quetiapine) is FDA-approved for treatment-resistant depression and has strong evidence in clinical trials. Thyroid hormone (T3) augmentation has older but still meaningful evidence. Each has its own side effect profile and its own monitoring requirements.
Switching antidepressant class. Moving from an SSRI to an SNRI, to bupropion, to mirtazapine, or to a tricyclic antidepressant. About a third of people who don't respond to one class respond to another. Bupropion is often the choice when anhedonia is the persistent symptom; mirtazapine is often the choice when sleep and appetite are the persistent symptoms.
Transcranial magnetic stimulation (TMS). A noninvasive brain stimulation treatment delivered as outpatient sessions (typically five days a week for six weeks). FDA-approved for treatment-resistant depression. About half of patients who try TMS respond. Sessions are about half an hour each. Side effects are usually limited to mild scalp discomfort and occasional headache.
Intranasal esketamine (Spravato). Rapid-acting medication delivered in a clinical setting (because of its dissociative effects and a small risk of misuse). FDA-approved specifically as an augmentation for treatment-resistant depression. Response often begins within days to weeks rather than the typical six-week window of traditional antidepressants. Used alongside an oral antidepressant.
IV ketamine. Off-label (not FDA-approved for depression specifically) but with substantial published evidence for rapid antidepressant effects. Delivered in clinical settings by trained providers.
Electroconvulsive therapy (ECT). The most effective single treatment for severe depression. Underused because of cultural stigma that doesn't match the current state of the procedure (modern ECT is done under brief anesthesia, with significantly improved safety and side-effect profiles compared to historical practice). Especially appropriate when depression is life-threatening.
Finding the right kind of care
Treatment-resistant depression usually requires a different level of psychiatric care than the average primary care office can provide. Sequencing through the next-line options well takes time, careful tracking, willingness to try multiple approaches, and access to treatments (TMS, esketamine, ECT) that not every clinic provides.
Most psychiatrists in independent practice can manage augmentation strategies and antidepressant switches. TMS, esketamine, and ECT typically require referral to specific clinics or programs that offer them. Treatment-resistant depression programs at academic medical centers are often the highest level of care for complex cases.
Telepsychiatry can be the right level of care for many treatment-resistant cases, especially when the next-line options being considered are augmentation or class-switching. For TMS or ECT, in-person referral to a specific program is usually required. shrinkMD is one option for the telepsychiatry layer; it doesn't provide TMS or ECT directly but does manage referrals when those treatments become the right next step.
What recovery actually looks like
Most cases of treatment-resistant depression do eventually respond. The path is usually nonlinear: a partial response to one medication, no response to the next, full response to the third with augmentation; or no response to several medications, full response to TMS; or limited oral medication response, full response to esketamine. The pattern across the major studies (STAR*D being the largest) is that persistence through sequential trials produces meaningful response and remission in the majority of patients, even when the first few trials don't.
Recovery from treatment-resistant depression doesn't always look like recovery from a first depressive episode. Some people reach full remission and stay there. Some people stabilize at a meaningfully better baseline that isn't quite remission but is durably above what depression was. Some people enter a maintenance pattern (ongoing medication, regular check-ins, occasional adjustments) that keeps the depression managed rather than cured. Each of those outcomes is a real recovery.
The piece that often matters most isn't the specific next-line treatment that finally worked. It's having a clinician who treats treatment-resistant depression as a problem to keep solving rather than a story about why nothing helps. That distinction is often what changes the trajectory.
Sources
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision (DSM-5-TR). 2022.
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006.
- American Psychiatric Association. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, 3rd ed. 2010 (with 2016 supplement).
- U.S. Food and Drug Administration. Esketamine (Spravato) prescribing information. 2019, updated 2020.
- NICE Guideline NG222. Depression in adults: treatment and management. 2022.
Related
The Treatment-Resistant Depression Map. TMS for depression. Ketamine and esketamine. Bipolar depression.
